This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Practice Guideline

. 2006 Jun;47(6):1059-66.

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials

Lalitha K Shankar¹, John M Hoffman, Steve Bacharach, Michael M Graham, Joel Karp, Adriaan A Lammertsma, Steven Larson, David A Mankoff, Barry A Siegel, Annick Van den Abbeele, Jeffrey Yap, Daniel Sullivan; National Cancer Institute

Affiliations

PMID: 16741317

Free article

Practice Guideline

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials

Lalitha K Shankar et al. J Nucl Med. 2006 Jun.

Free article

. 2006 Jun;47(6):1059-66.

Authors

Lalitha K Shankar¹, John M Hoffman, Steve Bacharach, Michael M Graham, Joel Karp, Adriaan A Lammertsma, Steven Larson, David A Mankoff, Barry A Siegel, Annick Van den Abbeele, Jeffrey Yap, Daniel Sullivan; National Cancer Institute

Affiliation

¹ Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. shankarl@mail.nih.gov

PMID: 16741317

No abstract available

PubMed Disclaimer

Comment in

18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.
Larson SM, Schwartz LH. Larson SM, et al. J Nucl Med. 2006 Jun;47(6):901-3. J Nucl Med. 2006. PMID: 16741296 No abstract available.

Similar articles

18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.
Larson SM, Schwartz LH. Larson SM, et al. J Nucl Med. 2006 Jun;47(6):901-3. J Nucl Med. 2006. PMID: 16741296 No abstract available.
Monitoring cancer therapy with PET: probably effective, but more research is needed.
Lucignani G. Lucignani G. Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1520-5. doi: 10.1007/s00259-009-1214-x. Eur J Nucl Med Mol Imaging. 2009. PMID: 19593559 Review. No abstract available.
[Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P, Brusco S, Corone C, Devillers A, Foehrenbach H, Lumbroso JD, Maszelin P, Montravers F, Moretti JL, Rain JD, Talbot JN, Carretier J, Leichtnam-Dugarin L, Delavigne V, Philip T, Fervers B; Fédération nationale des centres de lutte contre le cancer (FNCLCC); Standards, Options: Recommendations; SFBMN; Ligue nationale contre le cancer; Fédération hospitalière de France; Fédération nationale de cancérologie des Centres hospitaliers régionaux et universitaires; Fédération française de cancérologie. Bourguet P, et al. Bull Cancer. 2005 Jul;92(7):723-32. Bull Cancer. 2005. PMID: 16123010 French.
Standards for PET image acquisition and quantitative data analysis.
Boellaard R. Boellaard R. J Nucl Med. 2009 May;50 Suppl 1:11S-20S. doi: 10.2967/jnumed.108.057182. Epub 2009 Apr 20. J Nucl Med. 2009. PMID: 19380405 Review.
[Technical Approaches for Quantitative Treatment Responses Using 18F-FDG PET].
Miwa K, Miyaji N, Umeda T, Murata T, Wagatsuma K, Sasaki M. Miwa K, et al. Igaku Butsuri. 2015;35(1):30-8. Igaku Butsuri. 2015. PMID: 26753394 Review. Japanese.

See all similar articles

Cited by

FDG-PET Response Prediction in Pediatric Hodgkin's Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value.
Hussien AE, Furth C, Schönberger S, Hundsdoerfer P, Steffen IG, Amthauer H, Müller HW, Hautzel H. Hussien AE, et al. Cancers (Basel). 2015 Jan 28;7(1):287-304. doi: 10.3390/cancers7010287. Cancers (Basel). 2015. PMID: 25635760 Free PMC article.
Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort.
Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Cheedella NK, et al. Ann Oncol. 2013 May;24(5):1262-6. doi: 10.1093/annonc/mds617. Epub 2012 Dec 17. Ann Oncol. 2013. PMID: 23247658 Free PMC article.
Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer.
Hu Y, Tian M, Zhang H. Hu Y, et al. J Biomed Biotechnol. 2012;2012:419402. doi: 10.1155/2012/419402. Epub 2012 Mar 21. J Biomed Biotechnol. 2012. PMID: 22529706 Free PMC article. Review.
Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study.
Tőkés T, Szentmártoni G, Torgyík L, Kajáry K, Lengyel Z, Györke T, Molnár BÁ, Tőkés AM, Kulka J, Dank M. Tőkés T, et al. Croat Med J. 2015 Apr;56(2):128-38. doi: 10.3325/cmj.2015.56.128. Croat Med J. 2015. PMID: 25891872 Free PMC article.
The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy.
Coughlan M, Elstrom R. Coughlan M, et al. Cancer Imaging. 2014 Nov 29;14(1):34. doi: 10.1186/s40644-014-0034-9. Cancer Imaging. 2014. PMID: 25608713 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information